Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma
Pharmaceuticals · 11.08.2024 · 17 (8) · 1057
DOI: 10.3390/ph17081057 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 11.08.2024. Verfasst von Zizhuo Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Molecular Imaging, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Techno…. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hypoxia is a hallmark of solid tumors, including hepatocellular carcinoma (HCC). Hypoxia has proven to be involved in multiple tumor biological processes and associated with malignant progression and resistance to therapy. Transarterial chemoembolization (TACE) is a well-established locoregional therapy for patients with unresectable HCC. However, TACE-induced hypoxia regulates tumor angiogenesis, energy metabolism, epithelial-mesenchymal transition (EMT), and immune processes through hypoxia-inducible factor 1 (HIF-1), which may have adverse effects on the therapeutic efficacy of TACE. Hypoxia has emerged as a promising target for combination with TACE in the treatment of HCC. This review summarizes the impact of hypoxia on HCC tumor biology and the adverse effects of TACE-induced hypoxia on its therapeutic efficacy, highlighting the therapeutic potential of hypoxia-targeted therapy in combination with TACE for HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubei Key Laboratory of Molecular Imaging, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan 430022, China.
- Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zitieren
APA
Wang, Z., Li, Q., & Liang, B. (2024). Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma. Pharmaceuticals, 17(8), 1057. https://doi.org/10.3390/ph17081057
Vancouver
Wang Z, Li Q, Liang B. Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma. Pharmaceuticals. 2024;17(8):1057. doi:10.3390/ph17081057
BibTeX
@article{Wang2024,
author = {Wang, Zizhuo and Li, Qing and Liang, Bin},
title = {Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {8},
pages = {1057},
doi = {10.3390/ph17081057}
}
EUVIMED